---
title: "Palvella Therapeutics appoints Savara CEO Matt Pauls to board of directors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291274756.md"
description: "Palvella Therapeutics has appointed Matt Pauls, CEO of Savara, to its board of directors. This move supports Palvella's preparation for the potential US launch of QTORIN rapamycin. Pauls brings extensive experience, having previously led Strongbridge Biopharma through its Nasdaq IPO and commercial launches, and served as CCO at Insmed."
datetime: "2026-06-30T11:31:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291274756.md)
  - [en](https://longbridge.com/en/news/291274756.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291274756.md)
generator: "portal-rs"
---

# Palvella Therapeutics appoints Savara CEO Matt Pauls to board of directors

-   Palvella Therapeutics appointed Matt Pauls to its board as it prepares for a potential US launch of QTORIN rapamycin. \* Pauls is chair and CEO of Savara, a clinical-stage company focused on rare respiratory diseases. \* He previously led Strongbridge Biopharma as president and CEO, steering its Nasdaq IPO and commercial launches of KEVEYIS and Macrilen. \* Pauls also served as chief commercial officer at Insmed, leading global commercial and technical operations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300730PRIMZONEFULLFEED9754200) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)
- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

- [Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294958978.md)
- [Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $642,194.57](https://longbridge.com/en/news/293070502.md)
- [Elicera Therapeutics names Johan Liwing CEO](https://longbridge.com/en/news/296185226.md)
- [IRLAB Therapeutics to webcast interim report presentation](https://longbridge.com/en/news/296470410.md)
- [BrainStorm Cell Therapeutics GAAP EPS of -$0.35](https://longbridge.com/en/news/296069988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**